Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Stefansson

Showing results (31-40 of 69) with videos related to

Pageof 7
Sort By:
International Journal of Oncology|January 19, 2008
HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomasIngeborg B Engelsen, Ingunn M Stefansson, Rameen Beroukhim, et al.
Gynecologic Oncology|July 7, 2009
Plasma calprotectin concentrations in women with endometrial carcinomaHannah Ni Bhriain, Jone Trovik, Elisabeth Wik, et al.
Breast Cancer Research and Treatment|September 28, 2011
Vascular proliferation is a prognostic factor in breast cancerJarle B Arnes, Ingunn M Stefansson, Oddbjørn Straume, et al.
Journal of the National Cancer Institute|October 2, 2003
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancerWilliam D Foulkes, Ingunn M Stefansson, Pierre O Chappuis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancerKarin Collett, Geir E Eide, Jarle Arnes, et al.
Scientific Reports|February 10, 2021
Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancerKristi Krüger, Laxmi Silwal-Pandit, Elisabeth Wik, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 17, 2005
A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumorsKarin Collett, Ingunn M Stefansson, Johan Eide, et al.
The American Journal of Pathology|February 2, 2011
Gene expression patterns related to vascular invasion and aggressive features in endometrial cancerMonica Mannelqvist, Ingunn M Stefansson, Geir Bredholt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2005
EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breastIngeborg M Bachmann, Ole J Halvorsen, Karin Collett, et al.
American Journal of Obstetrics and Gynecology|October 6, 2009
Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic settingElisabeth Wik, Jone Trovik, Ole E Iversen, et al.
Pageof 7

Showing results (31-40 of 69) with videos related to

Sort By:
Pageof 7
International Journal of Oncology|January 19, 2008
HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomasIngeborg B Engelsen, Ingunn M Stefansson, Rameen Beroukhim, et al.
Gynecologic Oncology|July 7, 2009
Plasma calprotectin concentrations in women with endometrial carcinomaHannah Ni Bhriain, Jone Trovik, Elisabeth Wik, et al.
Breast Cancer Research and Treatment|September 28, 2011
Vascular proliferation is a prognostic factor in breast cancerJarle B Arnes, Ingunn M Stefansson, Oddbjørn Straume, et al.
Journal of the National Cancer Institute|October 2, 2003
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancerWilliam D Foulkes, Ingunn M Stefansson, Pierre O Chappuis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancerKarin Collett, Geir E Eide, Jarle Arnes, et al.
Scientific Reports|February 10, 2021
Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancerKristi Krüger, Laxmi Silwal-Pandit, Elisabeth Wik, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 17, 2005
A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumorsKarin Collett, Ingunn M Stefansson, Johan Eide, et al.
The American Journal of Pathology|February 2, 2011
Gene expression patterns related to vascular invasion and aggressive features in endometrial cancerMonica Mannelqvist, Ingunn M Stefansson, Geir Bredholt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2005
EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breastIngeborg M Bachmann, Ole J Halvorsen, Karin Collett, et al.
American Journal of Obstetrics and Gynecology|October 6, 2009
Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic settingElisabeth Wik, Jone Trovik, Ole E Iversen, et al.
Pageof 7